The STING pathway is a bridge to connect innate and adaptive immunities.31 STING agonists have been demonstrated to elicit or augment anti-tumor immune responses in a myriad of pre-clinical studies32 and exhibit a synergistic effect with radiotherapy.24 The currently published phase I and dose-escalation clinical trials, however, reveal that the clinical activity of STING agonists is far lower than expected based on the potent antitumor activity observed in pre-clinical models. This evidence concerns the gene STING1 and neoplasm.